胶质母细胞瘤靶向治疗:近期生物学进展与试验更新
本文综述胶质母细胞瘤(WHO IV级星形细胞瘤)靶向治疗的生物学基础与临床试验进展,涵盖生长因子受体及下游通路、细胞周期与表观遗传调控、血管生成和抗肿瘤免疫等方向;尽管偶见靶向治疗应答,迄今尚无靶向治疗在临床试验中被正式验证有效。
要点
- 胶质母细胞瘤为成人最常见的原发性脑肿瘤,异质性强、治疗难度大。
- 基于分子特征匹配的现代试验设计已用于靶向药物评估。
- 迄今尚无靶向治疗在临床试验中被正式验证有效。
核心结论
- 尽管偶见靶向治疗应答的个案记录,迄今尚无靶向治疗在临床试验中被正式验证对胶质母细胞瘤有效。
研究设计与样本
- 综述:汇总胶质母细胞瘤靶向治疗相关的生物学进展与评估靶向治疗及免疫治疗的近期临床试验数据。
主要发现
- 针对肿瘤生长因子受体及下游通路、细胞周期与表观遗传调控、血管生成和抗肿瘤免疫反应的多种合理策略正在研究中。
- 近期预后与预测生物标志物的识别和验证,使基于肿瘤分子特征匹配靶向药物的现代试验设计得以实施。
- 缺乏对体内相关分子驱动因素的了解,以及缺乏高生物活性且可透过血脑屏障的靶向治疗,仍是显著挑战。
临床怎么用
- 综述讨论靶向药物在胶质母细胞瘤中开发的挑战与机遇,未给出具体推荐条款。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults, representing a highly heterogeneous group of neoplasms that are among the most aggressive and challenging cancers to treat. An improved understanding of the molecular pathways that drive malignancy in glioblastoma has led to the development of various biomarkers and the evaluation of several agents specifically targeting tumor cells and the tumor microenvironment. A number of rational approaches are being investigated, including therapies targeting tumor growth factor receptors and downstream pathways, cell cycle and epigenetic regulation, angiogenesis and antitumor immune response. Moreover, recent identification and validation of prognostic and predictive biomarkers have allowed implementation of modern trial designs based on matching molecular features of tumors to targeted therapeutics. However, while occasional targeted therapy responses have been documented in patients, to date no targeted therapy has been formally validated as effective in clinical trials. The lack of knowledge about relevant molecular drivers in vivo combined with a lack of highly bioactive and brain penetrant-targeted therapies remain significant challenges. In this article, we review the most promising biological insights that have opened the way for the development of targeted therapies in glioblastoma, and examine recent data from clinical trials evaluating targeted therapies and immunotherapies. We discuss challenges and opportunities for the development of these agents in glioblastoma.
引用
- Touat M, Idbaih A, Sanson M, et al. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017. PMID: 28863449. doi:10.1093/annonc/mdx106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。